clozapine | CARLAT PUBLISHING

What’s Wrong with Mental Health Care?

December 9, 2024

Kellie Newsome, PMHNP, Chris Aiken, MD, and Nicholas Rosenlicht, MD

We talk with Nick Rosenlicht, MD about what’s gone wrong in the mental health care system.

Clinical Update

Clozapine: Monitoring With Skill

April 1, 2024

Nicole Turnier, MD.

Nicole Turnier, MD. Psychiatrist, Rochester Center for Behavioral Medicine, Rochester Hills, MI.

Dr. Turnier has no financial relationships with companies related to this material.

Few medications are as complex to use as clozapine. This guide will equip you with the necessary knowledge and insights to prescribe it, monitor for side effects, and recognize key risks.

Research Update

Surprise Result for Adherence in Bipolar Disorder

November 9, 2023

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Lithium’s reputation as a difficult med may have more to do with branding than reality, according to this large analysis of mood stabilizer adherence.

Psychopharm Commandment #10: Don’t Fear these Meds

May 29, 2023

Kellie Newsome, PMHNP and Chris Aiken, MD

Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

Clozapine for Conduct Disorder in Schizophrenia

March 23, 2022

Anne Li, MD.

Anne Li, MD. Dr. Li has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Clozapine appears more effective than other antipsychotic medications in reducing violent behavior among patients with schizophrenia and a history of conduct disorder.

Sublingual Atropine Drops and Clozapine-Induced Drooling

March 23, 2022

Sébastien Hardy, PharmD, BCPS.

Sébastien Hardy, PharmD, BCPS. Dr. Hardy has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Sialorrhea, or excessive salivation, is a distressing side effect from clozapine. Sublingual atropine drops help reduce clozapine-induced hypersalivation.

EXPERT Q&A

Raising the Bar in Schizophrenia Treatment

January 31, 2022

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH Professor of Psychiatry at the Medical College of Georgia, Augusta, and President of the Georgia Psychiatric Physicians Association. Dr. Miller receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute.

Dr. Miller discusses new options for negative symptoms, how to improve the therapeutic alliance, and what to do when clozapine doesn’t work in schizophrenia.

EXPERT Q&A

The Schizophrenia-OCD Overlap

September 28, 2021

Michael Poyurovsky, MD

Michael Poyurovsky, MD

Ma’ale HaCarmel Mental Health Center, Tirat Carmel, Israel; Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. Dr. Poyurovsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

OCD and schizophrenia often overlap, but treatment of this comorbidity is risky terrain. Dr. Poyurovsky explains when antidepressants should be avoided and details which antipsychotics are more likely to exacerbate OCD and which ones are more likely to help it.

Weight Gain and Metabolic Side Effects

July 14, 2021

Stephen Marder, MD

Stephen Marder, MD

Daniel X. Freedman Professor of Psychiatry. Vice Chair for Education, Semel Institute for Neuroscience at UCLA. Director, VA VISN 22 Mental Illness Research, Education, and Clinical Center, San Diego, CA.

Dr. Marder has disclosed no relevant financial or other interests in any commercial companies pertaining to educational activity.

Dr. Steve Marder describes interventions to minimize patients’ antipsychotic-induced weight gain and insulin resistance.

Tips on Choosing an Antipsychotic for Schizophrenia

August 26, 2020

Which antipsychotics should we consider selecting as the first-line and second-line treatments, and what should we base this decision on? Dr. Aziz addresses this in a past article from The Carlat Psychiatry Report. Here’s some of his advice:Process: Tolerability instead of efficacy should be considered when selecting a first-line treatment.